Tumor-derived PCs seem to upregulate PD-L1 expression, a negative regulator of anti-tumor T cell responses, and overexpress the PC marker RGS5, which, together with IL-6, modulates the expression of the adhesion molecule ICAM-1 and promotes T-cell anergy [51]. Here, RGS5 is linked to neoplasm.